Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Liabilities and Shareholders Equity: 2010-2025

Historic Liabilities and Shareholders Equity for Ani Pharmaceuticals (ANIP) over the last 15 years, with Sep 2025 value amounting to $1.4 billion.

  • Ani Pharmaceuticals' Liabilities and Shareholders Equity rose 9.38% to $1.4 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $5.3 billion, marking a year-over-year increase of 32.29%. This contributed to the annual value of $1.3 billion for FY2024, which is 41.94% up from last year.
  • According to the latest figures from Q3 2025, Ani Pharmaceuticals' Liabilities and Shareholders Equity is $1.4 billion, which was up 4.85% from $1.3 billion recorded in Q2 2025.
  • Ani Pharmaceuticals' Liabilities and Shareholders Equity's 5-year high stood at $1.4 billion during Q3 2025, with a 5-year trough of $463.8 million in Q1 2021.
  • Over the past 3 years, Ani Pharmaceuticals' median Liabilities and Shareholders Equity value was $920.8 million (recorded in 2024), while the average stood at $1.1 billion.
  • Data for Ani Pharmaceuticals' Liabilities and Shareholders Equity shows a peak YoY increase of 67.31% (in 2021) and a maximum YoY decrease of 3.81% (in 2021) over the last 5 years.
  • Ani Pharmaceuticals' Liabilities and Shareholders Equity (Quarterly) stood at $771.6 million in 2021, then decreased by 1.49% to $760.1 million in 2022, then grew by 18.99% to $904.4 million in 2023, then soared by 41.94% to $1.3 billion in 2024, then rose by 9.38% to $1.4 billion in 2025.
  • Its Liabilities and Shareholders Equity stands at $1.4 billion for Q3 2025, versus $1.3 billion for Q2 2025 and $1.3 billion for Q1 2025.